Loading patent…
AssigneeUniversity of Virginia Patent Foundation
InventorsMark Kester, Pedro Filipe Da Costa Pinheiro, Jeremy Shaw
Estimating the term…
Provided are methods for treating cancers and/or tumors in subjects. In some embodiments, the methods include administering to a subject an effective amount of a ceramide nanoliposome (CNL), wherein the CNL has a lipid bilayer that includes one or more C2-C24 ceramides and encapsulates one or more anti-cancer and/or anti-tumor agents. Also provided are methods for treating cancers and/or tumors associated with receptor tyrosine kinase or nuclear receptor activities, methods for treating Prostate Cancer, methods for inhibiting growth of EGFR-dependent cancers and/or tumors, methods for inhibiting growth of androgen receptor negative cells, method for reducing or eliminating androgen receptor negative cells from subject, CNLs that encapsulate one or more anti-cancer and/or anti-tumor agents, wherein the CNLs include a lipid bilayer that has one or more C2-C24 ceramides, and pharmaceutical compositions that include the disclosed CNLs.
A method for treating a cancer and/or a tumor in a subject, the method comprising administering to the subject an effective amount of a ceramide nanoliposome (CNL), wherein the CNL comprises a lipid bilayer comprising one or more C2-C24 ceramides and encapsulates one or more anti-cancer and/or anti-tumor agents.
A method for treating a cancer and/or a tumor associated with activity of a receptor tyrosine kinase or a nuclear receptor in a subject, the method comprising administering to the subject an effective amount of a ceramide nanoliposome (CNL), wherein the CNL comprises a lipid bilayer comprising one or more C2-C24 ceramides and encapsulates one or more nuclear receptor inhibitors, one or more tyrosine kinase inhibitors, or a combination thereof.
A method for treating Prostate Cancer (PCa) in a subject, the method comprising administering to the subject an effective amount of a ceramide nanoliposome (CNL), wherein the CNL comprises a lipid bilayer comprising one or more C2-C24 ceramides and encapsulates one or more anti-cancer and/or anti-tumor agents.
A method for inhibiting growth of an EGFR-dependent cancer and/or tumor, the method comprising contacting the EGFR-dependent cancer or tumor with an effective amount of a ceramide nanoliposome (CNL), wherein the CNL comprises a lipid bilayer comprising one or more C2-C24 ceramides and encapsulates one or more anti-cancer and/or anti-tumor agents.
A method for inhibiting growth of an androgen receptor (AR) negative cell, the method comprising contacting the AR negative cell with an effective amount of a ceramide nanoliposome (CNL), wherein the CNL comprises a lipid bilayer comprising one or more C2-C24 ceramides and encapsulates one or more anti-cancer and/or anti-tumor agents.
A method of reducing or eliminating androgen receptor (AR) negative cells from a subject's prostate, the method comprising administering to the subject an effective amount of a ceramide nanoliposome (CNL) comprising a lipid bilayer comprising one or more C2-C24 ceramides and encapsulating one or more anti-cancer and/or anti-tumor agents, wherein the CNL contacts the AR negative cells and induces apoptosis thereof.
The method of any one of the preceding claims, wherein the subject is a mammal, optionally a human.
A ceramide nanoliposome (CNL) encapsulating one or more anti-cancer and/or anti-tumor agents, wherein the ceramide nanoliposome comprises a lipid bilayer comprising one or more C2-C24 ceramides and the one or more anti-cancer and/or anti-tumor agents are selected from the group consisting of tyrosine kinase receptor inhibitors and nuclear receptor inhibitors.
Dependencies are inferred from the claim text.